Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550224 | 0.91 | PIK3CD (0.39) | PIK3CDCYP2D6SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL1394110 | 0.80 | DRD2 (0.38) | PIK3CD | |
| SCHEMBL1394853 | 0.80 | DRD2 (0.38) | PIK3CD | |
| SCHEMBL5949826 | 0.80 | — | — | |
| SCHEMBL1394111 | 0.80 | DRD2 (0.38) | PIK3CD | |
| SCHEMBL24209746 | 0.80 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2SLC2A1HRH3 | |
| SCHEMBL2001262 | 0.80 | — | — | |
| SCHEMBL20438377 | 0.80 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2SLC2A1HRH3 | |
| SCHEMBL1621691 | 0.80 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2SLC2A1HRH3 | |
| SCHEMBL7721809 | 0.78 | LMNA (0.37) | PIK3CDALDH1A1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | claimed |
| CN-116284001-A | DCLK1 inhibitor, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-06-23 | — | — | CN | claimed |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | claimed |
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| CN-113423708-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-21 | — | — | CN | claimed |
| CN-108864007-B | 2-aminomethyl-6- (benzofuran-5-yl) phenol and preparation method and application thereof | 湖南大学 | 2020-08-04 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| WO-2019063704-A1 | SUBSTITUTED 3-PHENYLQUINAZOLIN-4(3H)-ONES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-04-04 | — | — | WO | claimed |
| WO-2019063708-A1 | SUBSTITUTED 3-PHENYLQUINAZOLIN-4(3H)-ONES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-04-04 | — | — | WO | claimed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | claimed |
| WO-2010001169-A2 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | WO | claimed |
| WO-2009078999-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | claimed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | claimed |
| EP-0891976-B1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMA (US) | 2002-10-16 | — | — | EP | claimed |
| US-6362169-B1 | Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith | KANEKA CORPORATION (JP) | 2002-03-26 | — | — | US | claimed |
| EP-1057487-A1 | ANTIMICROBIAL COMPOSITIONS WITH SYNERGISTIC EFFECT, DRUGS AND REMEDIES FOR DIGESTIVE DISEASES CONTAINING THE SAME, PROCESS FOR THE PRODUCTION THEREOF AND PREPARATIONS ASSOCIATED THEREWITH | KANEKA CORPORATION (JP) | 2000-12-06 | — | — | EP | claimed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| EP-0598046-B1 | CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMA (US) | 1999-03-24 | — | — | EP | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| US-4937240-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR9 | PIK3CD 603/4885CYP2D6 2538/4885SMN1; SMN2 884/4885 |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV4 | PIK3CD 911/4885CYP2D6 2706/4885SMN1; SMN2 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.